Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Infliximab
Remicade
Not routinely available
NICE (TA187 (SMC 363/07))
13/11/2019
Indication
Severe, active Crohn's disease
Therapeutic Area
Gastro-intestinal system
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
100mg powder for intravenous infusion
Comments
May 2010 - NICE MTA Advice: SMC Advice 363/07 is superseded by NICE TA187. November 2019 - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.
Link to Advice
Advice Published
19/05/2010